{"id":35308,"date":"2015-04-29T08:03:58","date_gmt":"2015-04-29T12:03:58","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=35308"},"modified":"2015-04-29T08:03:58","modified_gmt":"2015-04-29T12:03:58","slug":"merck-co-inc-s-nysemrk-new-cancer-immunotherapy-sales-beat-estimates","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-s-nysemrk-new-cancer-immunotherapy-sales-beat-estimates-35308","title":{"rendered":"Merck &#038; Co., Inc.\u2019s (NYSE:MRK) New Cancer Immunotherapy Sales Beat Estimates"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Merck &amp; Co., Inc.\u2019s (NYSE:MRK)<\/strong> new cancer therapy Keytruda posted sales of $83 million during 1Q. The sale was better than expected, however, the total revenue and drug sales have reduced from a year ago.<\/p>\n<p style=\"text-align: justify;\">Keytruda was approved last September and is Merck&#8217;s checkpoint inhibitor for advanced melanoma. The sales in 1Q rose 40% from $50 million in 4Q2014. The data was submitted by Merck to the U.S. Food and Drug Administration. The filing was done to seek expansion of Keytruda&#8217;s label to cover the treatment of patients with advanced non-small lung cancer patients. The company will make another filing to the USFDA seeking to expand Keytruda use in newly diagnosed melanoma patients later this year.<\/p>\n<p style=\"text-align: justify;\">Overall, the total sales in 1Q were $9.4 billion which was 8% lower than a year ago. The sales were, however, higher that the Street consensus sale of $9 billion. The lower sales have been attributed by Merck to the effects of foreign exchange.<\/p>\n<p style=\"text-align: justify;\">The pharmaceutical sales of Merck totalled $8.3 billion in 1Q; this represents a fall of 2% from a year ago. If we take away the negative effects of foreign exchange, then the sales would have risen by 5% in 1Q2015.<\/p>\n<p style=\"text-align: justify;\">Janumet and Januvia, Merck\u2019s diabetes drugs\u2019 sales have increased by 4% over the year to $1.4 billion. Merck has announced that an important heart safety study of Januvia has attained its primary goal.<\/p>\n<p style=\"text-align: justify;\">Remicade, Merck&#8217;s arthritis drug reported sales of $501 million; this is 17% drop from a year back. The cause for the drop is due to the loss of patent protection and production of copycats in Europe.<\/p>\n<p style=\"text-align: justify;\">The earnings per share of Merck &amp; Co., Inc.\u2019s (NYSE:MRK) for the first quarter is 85 cents which is higher than the 74 cents consensus earnings. The earning is, however, lower that the 88 cents per share the company posted a year back.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck &amp; Co., Inc.\u2019s (NYSE:MRK) new cancer therapy Keytruda posted sales of $83 million during 1Q. The sale was better than expected, however, the total [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":14597,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[11324,1123],"stock_ticker":[],"class_list":["post-35308","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-merck-co-inc-s-nysemrk","tag-nysemrk","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck &amp; Co., Inc.\u2019s (NYSE:MRK) New Cancer Immunotherapy Sales Beat Estimates - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-s-nysemrk-new-cancer-immunotherapy-sales-beat-estimates-35308\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck &amp; Co., Inc.\u2019s (NYSE:MRK) New Cancer Immunotherapy Sales Beat Estimates - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Merck &amp; Co., Inc.\u2019s (NYSE:MRK) new cancer therapy Keytruda posted sales of $83 million during 1Q. The sale was better than expected, however, the total [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-s-nysemrk-new-cancer-immunotherapy-sales-beat-estimates-35308\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-04-29T12:03:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Merck-Co-Logo-BIG.gif\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"329\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/gif\" \/>\n<meta name=\"author\" content=\"Greg Folin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Greg Folin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-s-nysemrk-new-cancer-immunotherapy-sales-beat-estimates-35308#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-s-nysemrk-new-cancer-immunotherapy-sales-beat-estimates-35308\"},\"author\":{\"name\":\"Greg Folin\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\"},\"headline\":\"Merck &#038; Co., Inc.\u2019s (NYSE:MRK) New Cancer Immunotherapy Sales Beat Estimates\",\"datePublished\":\"2015-04-29T12:03:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-s-nysemrk-new-cancer-immunotherapy-sales-beat-estimates-35308\"},\"wordCount\":314,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-s-nysemrk-new-cancer-immunotherapy-sales-beat-estimates-35308#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Merck-Co-Logo-BIG.gif\",\"keywords\":[\"Merck &amp; Co. Inc.\u2019s (NYSE:MRK)\",\"NYSE:MRK\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-s-nysemrk-new-cancer-immunotherapy-sales-beat-estimates-35308#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-s-nysemrk-new-cancer-immunotherapy-sales-beat-estimates-35308\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-s-nysemrk-new-cancer-immunotherapy-sales-beat-estimates-35308\",\"name\":\"Merck & Co., Inc.\u2019s (NYSE:MRK) New Cancer Immunotherapy Sales Beat Estimates - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-s-nysemrk-new-cancer-immunotherapy-sales-beat-estimates-35308#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-s-nysemrk-new-cancer-immunotherapy-sales-beat-estimates-35308#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Merck-Co-Logo-BIG.gif\",\"datePublished\":\"2015-04-29T12:03:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-s-nysemrk-new-cancer-immunotherapy-sales-beat-estimates-35308#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-s-nysemrk-new-cancer-immunotherapy-sales-beat-estimates-35308\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-s-nysemrk-new-cancer-immunotherapy-sales-beat-estimates-35308#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Merck-Co-Logo-BIG.gif\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Merck-Co-Logo-BIG.gif\",\"width\":1024,\"height\":329},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-s-nysemrk-new-cancer-immunotherapy-sales-beat-estimates-35308#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck &#038; Co., Inc.\u2019s (NYSE:MRK) New Cancer Immunotherapy Sales Beat Estimates\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\",\"name\":\"Greg Folin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"caption\":\"Greg Folin\"},\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck & Co., Inc.\u2019s (NYSE:MRK) New Cancer Immunotherapy Sales Beat Estimates - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-s-nysemrk-new-cancer-immunotherapy-sales-beat-estimates-35308","og_locale":"en_US","og_type":"article","og_title":"Merck & Co., Inc.\u2019s (NYSE:MRK) New Cancer Immunotherapy Sales Beat Estimates - Wall Street PR","og_description":"Merck &amp; Co., Inc.\u2019s (NYSE:MRK) new cancer therapy Keytruda posted sales of $83 million during 1Q. The sale was better than expected, however, the total [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-s-nysemrk-new-cancer-immunotherapy-sales-beat-estimates-35308","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2015-04-29T12:03:58+00:00","og_image":[{"width":1024,"height":329,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Merck-Co-Logo-BIG.gif","type":"image\/gif"}],"author":"Greg Folin","twitter_misc":{"Written by":"Greg Folin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-s-nysemrk-new-cancer-immunotherapy-sales-beat-estimates-35308#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-s-nysemrk-new-cancer-immunotherapy-sales-beat-estimates-35308"},"author":{"name":"Greg Folin","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e"},"headline":"Merck &#038; Co., Inc.\u2019s (NYSE:MRK) New Cancer Immunotherapy Sales Beat Estimates","datePublished":"2015-04-29T12:03:58+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-s-nysemrk-new-cancer-immunotherapy-sales-beat-estimates-35308"},"wordCount":314,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-s-nysemrk-new-cancer-immunotherapy-sales-beat-estimates-35308#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Merck-Co-Logo-BIG.gif","keywords":["Merck &amp; Co. Inc.\u2019s (NYSE:MRK)","NYSE:MRK"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-s-nysemrk-new-cancer-immunotherapy-sales-beat-estimates-35308#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-s-nysemrk-new-cancer-immunotherapy-sales-beat-estimates-35308","url":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-s-nysemrk-new-cancer-immunotherapy-sales-beat-estimates-35308","name":"Merck & Co., Inc.\u2019s (NYSE:MRK) New Cancer Immunotherapy Sales Beat Estimates - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-s-nysemrk-new-cancer-immunotherapy-sales-beat-estimates-35308#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-s-nysemrk-new-cancer-immunotherapy-sales-beat-estimates-35308#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Merck-Co-Logo-BIG.gif","datePublished":"2015-04-29T12:03:58+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-s-nysemrk-new-cancer-immunotherapy-sales-beat-estimates-35308#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-s-nysemrk-new-cancer-immunotherapy-sales-beat-estimates-35308"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-s-nysemrk-new-cancer-immunotherapy-sales-beat-estimates-35308#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Merck-Co-Logo-BIG.gif","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Merck-Co-Logo-BIG.gif","width":1024,"height":329},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-s-nysemrk-new-cancer-immunotherapy-sales-beat-estimates-35308#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Merck &#038; Co., Inc.\u2019s (NYSE:MRK) New Cancer Immunotherapy Sales Beat Estimates"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e","name":"Greg Folin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","caption":"Greg Folin"},"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/35308","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=35308"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/35308\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/14597"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=35308"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=35308"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=35308"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=35308"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}